- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.01. | Terumo BCT, FUJIFILM Irvine Scientific Partner on T Cell Expansion Solution | 2 | Contract Pharma | ||
| 10.12.24 | Terumo, Medis announce strategic partnership to enhance cardiovascular care | 5 | MassDevice | ||
| 04.12.24 | Terumo launches R2P NaviCross peripheral support catheter in US | 6 | MassDevice | ||
| 07.11.24 | Terumo reports 1H results | 4 | Seeking Alpha | ||
| 31.10.24 | Terumo BCT Expands Automation Offerings in Latin America | 3 | Contract Pharma | ||
| TERUMO CORPORATION ADR Aktie jetzt für 0€ handeln | |||||
| 16.10.24 | NAMSA und TERUMO kündigen strategische Outsourcing-Partnerschaft an | 225 | Business Wire | Die klinischen Forschungs-, Test- und Beratungsdienste von NAMSA werden dazu beitragen, die behördliche Zulassung des Medizinprodukteportfolios von TERUMO auf globaler Ebene zu beschleunigen. NAMSA... ► Artikel lesen | |
| 15.10.24 | NAMSA and TERUMO Announce Strategic Outsourcing Partnership | 453 | Business Wire | NAMSA's clinical research, testing and consulting services will help accelerate the regulatory approval of TERUMO's medical device portfolio on a global level. NAMSA, a world-leading MedTech... ► Artikel lesen | |
| 13.09.24 | MicroVention firmiert in Terumo Neuro um - Ausdruck eines erweiterten Fokus und strategischen Wachstums | 365 | Business Wire | MicroVention, Inc., ein weltweit führendes Unternehmen im Bereich neurovaskulärer Innovationen und eine hundertprozentige Tochtergesellschaft der Terumo Corporation, gab heute die offizielle Umbenennung... ► Artikel lesen | |
| 12.09.24 | MicroVention rebrands to Terumo Neuro | 2 | MassDevice | ||
| 12.09.24 | MicroVention Rebrands to Terumo Neuro - Reflects Expanded Focus and Strategic Growth | 399 | Business Wire | MicroVention, Inc., a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced its official rebranding to Terumo Neuro, effective immediately.... ► Artikel lesen | |
| 21.08.24 | Terumo-Aktie leicht im Plus (17,05 €) | 362 | ARIVA.de | Die Aktie von Terumo notiert am Mittwoch fester. Das Wertpapier kostete zuletzt 17,05 Euro. Das Wertpapier von Terumo verzeichnet aktuell einen Preisanstieg von 4,92 Prozent. Es hat sich um 80 Cent... ► Artikel lesen | |
| 08.08.24 | Terumo reports Q1 results | 4 | Seeking Alpha | ||
| 06.08.24 | Guter Tag für Terumo-Aktionäre: Aktienkurs steigt deutlich (15,15 €) | 364 | ARIVA.de | Zu den großen Gewinnern an der Börse zählt heute das Wertpapier von Terumo . Der Kurs des Anteilsscheins legt kräftig zu. Die Aktie von Terumo gehört heute mit einem Kursplus von 5,94 Prozent zu den... ► Artikel lesen | |
| 06.08.24 | Terumo Corporation: Terumo Establishes Corporate Venture Capital "Terumo Ventures" | 377 | PR Newswire | TOKYO, Aug. 6, 2024 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced that it has established "Terumo Ventures," a Corporate Venture Capital (CVC) organization responsible for... ► Artikel lesen | |
| 28.05.24 | Terumo Cardiovascular Announces 510(K) Clearance for the CDI OneView Monitoring System | 243 | PR Newswire | All-new modular, expandable design displays up to 22 vital patient parameters with real-time convenience ANN ARBOR, Mich., May 28, 2024 /PRNewswire/ -- Terumo Cardiovascular, a global leader in... ► Artikel lesen | |
| 03.04.24 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 03.04.2024 | 606 | Xetra Newsboard | The following instruments on XETRA do have their first trading 03.04.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 03.04.2024
Aktien
1 LU2791994721 Auna S.A.
2 US86959X1072... ► Artikel lesen | |
| 14.02.24 | Terumo Blood and Cell Technologies: Hundreds of sickle cell patients to benefit from £1.5M technology investment | 913 | PR Newswire | LONDON, Feb. 14, 2024 /PRNewswire/ -- Children, young people, and adults across England suffering from sickle cell disease will soon benefit from better care closer to where they live, following... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 85,77 | +0,07 % | Medtronic Appoints Thierry Pieton As CFO | WASHINGTON (dpa-AFX) - Medtronic Plc (MDT), a healthcare technology company, said on Tuesday that it has appointed Thierry Pieton as its Chief Financial Officer with effect from March 3. Pieton... ► Artikel lesen | |
| HCA HEALTHCARE | 298,40 | -3,68 % | ROUNDUP: HCA Healthcare Q4 Beats Market, Sees Growth In FY25; Declares Dividend | WASHINGTON (dpa-AFX) - HCA Healthcare, Inc. (HCA), while reporting weak fourth-quarter profit, but above market estimates, on Friday issued fiscal 2025 outlook, higher than last year, and announced... ► Artikel lesen | |
| LANTHEUS | 93,36 | -0,34 % | Radiopharm Theranostics: Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia | RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial collaboration will focus on a Phase 1 imaging trialFinancial incentives to be paid to RAD upon... ► Artikel lesen | |
| AMEDISYS | 87,50 | +0,57 % | Amedisys, Inc.: Amedisys Reports Third Quarter 2024 Financial Results | BATON ROUGE, La., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2024. Three-Month... ► Artikel lesen | |
| ENVISTA | 20,200 | -1,94 % | 5 Analysts Have This To Say About Envista Holdings | ||
| CAREDX | 21,510 | -4,36 % | Here's Why CareDx (CDNA) Traded Lower in Q4 | ||
| SYNEOS HEALTH | - | - | Research Solutions, Inc.: Research Solutions Reports Fiscal First Quarter 2025 Results | Reports 60% Increase in ARR to $17.6 Million, Positive Net Income and Cash Flow, Adjusted EBITDA of $1.3 Million HENDERSON, Nev., Nov. 14, 2024 /PRNewswire/ -- Research Solutions, Inc.... ► Artikel lesen | |
| CARMAT | 1,074 | -0,92 % | CARMAT Announces Its Participation in Several Scientific and Investor Conferences During the 1st Half of 2025 | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
| GT BIOPHARMA | 2,440 | 0,00 % | GT Biopharma files for automatic mixed securities shelf | ||
| CHEMOMETEC | 68,35 | +0,15 % | Chemometec A/S: Upgrade of revenue and operating profit guidance | ANNOUNCEMENT NO. 286 10 January 2025 Upgrade of revenue and operating profit guidance ChemoMetec sustained its positive performance in the second quarter of 2024/25 with better-than-expected sales... ► Artikel lesen | |
| HAMILTON THORNE | 1,490 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.12.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 02.12.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.12.2024ISIN NameCA81012R1064 SCOTTIE... ► Artikel lesen | |
| POLAREAN IMAGING | 0,001 | -94,12 % | Polarean Imaging plc: Appointment of Chase Hall, M.D., as Chief Medical Advisor | DURHAM, NC and LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging ("MRI") of the lungs, announces... ► Artikel lesen | |
| DEVYSER DIAGNOSTICS | 10,650 | 0,00 % | Devyser Diagnostics AB: Devyser publishes preliminary result for Q4 2024 | In light of this morning's communication that Fredrik Alpsten is leaving his position as CEO of Devyser and to avoid speculation, Devyser is releasing a summary of the year-end report for 2024 before... ► Artikel lesen | |
| ARRAIL GROUP | 0,242 | 0,00 % | ARRAIL GROUP (06639): 2024/2025 INTERIM REPORT | ||
| FRESENIUS | 36,720 | -0,22 % | Leichte Zugewinne bei der Fresenius SE & Co. KGaA-Aktie (36,58 €) | Das Wertpapier von Fresenius SE & Co. KGaA notiert heute fester. Der jüngste Kurs betrug 36,58 Euro. Die Fresenius+Co KgaA-Aktie verzeichnet gegenwärtig einen Wertanstieg von 2,75 Prozent. Sie hat sich... ► Artikel lesen |
Das Unternehmen TERUMO CORPORATION ADR kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,69 % bei einem Aktienkurs von 18,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TERUMO CORPORATION ADR finden Sie auf Wallstreet Online.
